Related Experiment Videos
Treating the patient with mild hypertension and renal insufficiency
Insights
Treating mild hypertension (90-104 mm Hg diastolic) reduces coronary heart disease risks. Prazosin offers a safe initial therapy option for hypertension with renal insufficiency, avoiding adverse effects of other drugs.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Mild hypertension (90-104 mm Hg diastolic) treatment reduces coronary heart disease (CHD) morbidity and mortality.
- Blood pressure reduction benefits patients with renal disease, heart failure, and cerebrovascular disease.
- Uncontrolled hypertension can worsen renal function and lead to complications like atherosclerosis.
Purpose of the Study:
- To evaluate prazosin as an initial antihypertensive therapy for patients with mild to moderate hypertension and renal insufficiency.
- To compare prazosin's efficacy and side effect profile against standard stepped-care therapies.
Main Methods:
- Review of existing studies on hypertension treatment and complications.
- Analysis of prazosin's mechanism of action, efficacy, and effects on lipids and renal function.
- Comparison of prazosin's hemodynamic effects with those of diuretics and beta-blockers.
Main Results:
- Standard therapies (diuretics, beta-blockers) are under reevaluation due to adverse effects on lipids and renal function.
- Beta-blockers can increase peripheral resistance, counteracting desired hemodynamic effects.
- Prazosin, a vasodilator, demonstrates efficacy without adverse effects on lipids or renal function and lowers peripheral resistance.
Conclusions:
- Prazosin is a suitable initial therapy choice for mild to moderate hypertension, especially in patients with renal insufficiency.
- Prazosin offers a favorable alternative to standard therapies due to its mechanism of action and side effect profile.
- Prazosin effectively manages hypertension while mitigating risks associated with renal compromise.
Abstract:
The Hypertension Detection and Follow-up Program (HDFP) first demonstrated that treatment of patients with mild hypertension (90 to 104 mm Hg diastolic) could reduce morbidity and mortality in coronary heart disease (CHD). Previous studies had already shown the beneficial effect of blood pressure reduction on renal disease, heart failure, and cerebrovascular disease. When uncontrolled, mild hypertension in the patient with renal disease will lead to further deterioration of renal function. To prevent this and other complications (such as atherosclerosis) of hypertension, whether primary or secondary, one should place these patients on antihypertensive therapy. However, standard stepped-care therapy with diuretic drugs and beta-blocking agents is now under reevaluation in view of the potential adverse effect of these agents on serum lipids and renal function. Beta-blocking drugs, furthermore, tend to increase peripheral resistance, a hemodynamic effect opposite to that desired in these patients. Other drugs, acting centrally or peripherally on the nervous system, also have some undesirable features in addition to troublesome side effects. Prazosin, a vasodilator and effective antihypertensive agent with a different mechanism of action, has no adverse action on lipids and renal function, lowers peripheral resistance, and does not cause many of the side effects that limit use of the other drugs. It therefore appears to be a good choice for initial therapy in mild to moderate hypertension with associated renal insufficiency.